CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

Table 1 Results of randomized placebo-controlled clinical trials with CGRP mAb for the treatment of episodic migraine

	Phase	MMD baseline	Exclusion by failed preventives	Study duration (weeks)	Treatment arms	N	MMD change versus placebo	Dropout ratio	Reference	Acronym/NCT
Eptinezumab	II	≥5	-	8	placebo	82		0%	Dodick et al, 2014	NCT01772524
	II	≥5	-	8	1000mg	81	-1.0	0%	Dodick et al, 2014	NCT01772524
	III	≥4	-	12	placebo	222		3%	Ashina et al, 2020	PROMISE-1
					100mg	221	-0.7	3%
					300mg	222	-1.1	2%
Fremanezumab	II	≥8	>2	12	placebo	104		0%	Bigal et al, 2015	NCT02025556
					225mg	96	-2.8	4%
					675mg monthly	96	-2.6	2%
	III	≥4	≥2	12	placebo	294		2%	Dodick et al, 2018	HALO
					225mg	289	-1.5	1%
					675mg	291	-1.3	2%
	II/III	≥4	≥2	12	placebo	117		1%	Sakai et al, 2021	NCT03303092
					225mg	121	-3.0	1%
					675mg	119	-3.0	0%
Galcanezumab	II	≥4	>2	12	placebo	110		1%	Dodick et al, 2014	NCT01625988
	II	≥4	>2	12	150mg every 2 weeks	107	-1.2	0%	Dodick et al, 2014	NCT01625988
	II	≥4	>2	12	placebo	137		0%	Sklajarevski et al, 2018	NCT02163993
					120mg	70	-0.9	0%
					300mg	67	-0.9	1%
	III	≥4	>2	24	placebo	433		2%	Stauffer et al, 2018	EVOLVE-1
					120mg (^a240mg)	213	-1.9	4%
					240mg	212	-1.8	3%
	III	≥4	>2	24	placebo	461		2%	Sklajarevski et al, 2018	EVOLVE-2
					120mg (^a240mg)	231	-2.0	2%
					240mg	223	-1.9	4%
Erenumab	II	≥4	>2	12	placebo	153		1%	Sun et al, 2016	NCT01952574
	II	≥4	>2	12	70mg	106	-1.1	3%	Sun et al, 2016	NCT01952574
	II	≥4	>2	24	placebo	136		1%	Sakai et al, 2019	NCT02630459
					70mg	135	-2.3	1%
					140mg	137	-1.9	0%
	III	≥4	>2	24	placebo	319		3%	Goadsby et al, 2017	STRIVE
					70mg	314	-1.4	2%
					140mg	319	-1.9	2%
	III	≥4	>2	12	placebo	289		0%	Dodick et al, 2018	ARISE
	III	≥4	>2	12	70mg	283	-1.0	2%	Dodick et al, 2018	ARISE
	III	≥4	>2	12	placebo	338		1%	Wang et al, 2021	EMPOwER
					70mg	338	-1.1	0%
					140mg	224	-1.7	0%

Unless indicated differently, dosing is monthly for erenumab, galcanezumab and fremanezumab 225mg and every 3 months for eptinezumab and fremanezumab 675mg
MMD monthly migraine days (for the group average MMD reduction only dosages in bold were used), NA not available
^aloading dosage

ISSN: 1129-2377